Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement
The purpose of this study was to evaluate the clinical safety of pamidronate when administered at a mean dosage of 1.0 mg/kg IV q28d in 33 tumor-bearing dogs. Biochemical tests of renal function were evaluated before each successive pamidronate treatment. Of 33 dogs treated with pamidronate, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. The biologic activity of IV pamidronate was assessed prospectively in 10 dogs with appendicular osteosarcoma and was assessed on reductions in urine N-telopeptide excretion (P = .042) and enhanced bone mineral density of the primary tumor measured with dual-energy x-ray absorptiometry (P = .024). Additionally, in these 10 dogs, pamidronate's therapeutic activity was supported by subjective improvement in pain control in 4 of the 10 dogs treated. IV pamidronate appears clinically safe in tumor-bearing dogs and may possess modest biologic activity for managing neoplastic complications associated with pathologic bone resorption.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of veterinary internal medicine - 19(2005), 1 vom: 29. Jan., Seite 74-80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fan, Timothy M [VerfasserIn] |
|---|
| Themen: |
9007-34-5 |
|---|
| Anmerkungen: |
Date Completed 29.03.2005 Date Revised 13.05.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM15371896X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM15371896X | ||
| 003 | DE-627 | ||
| 005 | 20231223064559.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0513.xml |
| 035 | |a (DE-627)NLM15371896X | ||
| 035 | |a (NLM)15715051 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fan, Timothy M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2005 | ||
| 500 | |a Date Revised 13.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The purpose of this study was to evaluate the clinical safety of pamidronate when administered at a mean dosage of 1.0 mg/kg IV q28d in 33 tumor-bearing dogs. Biochemical tests of renal function were evaluated before each successive pamidronate treatment. Of 33 dogs treated with pamidronate, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. The biologic activity of IV pamidronate was assessed prospectively in 10 dogs with appendicular osteosarcoma and was assessed on reductions in urine N-telopeptide excretion (P = .042) and enhanced bone mineral density of the primary tumor measured with dual-energy x-ray absorptiometry (P = .024). Additionally, in these 10 dogs, pamidronate's therapeutic activity was supported by subjective improvement in pain control in 4 of the 10 dogs treated. IV pamidronate appears clinically safe in tumor-bearing dogs and may possess modest biologic activity for managing neoplastic complications associated with pathologic bone resorption | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Collagen Type I |2 NLM | |
| 650 | 7 | |a Diphosphonates |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a collagen type I trimeric cross-linked peptide |2 NLM | |
| 650 | 7 | |a Collagen |2 NLM | |
| 650 | 7 | |a 9007-34-5 |2 NLM | |
| 650 | 7 | |a Pamidronate |2 NLM | |
| 650 | 7 | |a OYY3447OMC |2 NLM | |
| 700 | 1 | |a de Lorimier, Louis-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Charney, Sarah C |e verfasserin |4 aut | |
| 700 | 1 | |a Hintermeister, John G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of veterinary internal medicine |d 1996 |g 19(2005), 1 vom: 29. Jan., Seite 74-80 |w (DE-627)NLM012980854 |x 1939-1676 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2005 |g number:1 |g day:29 |g month:01 |g pages:74-80 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2005 |e 1 |b 29 |c 01 |h 74-80 | ||